Navigation Links
QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
Date:8/22/2007

Multicenter Study Enrolls More Than 800 Women to Evaluate QuatRx's

New-Generation Selective Estrogen Receptor Modulator (SERM)

ANN ARBOR, Mich., Aug. 22 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company focused on development and commercialization of compounds to treat endocrine, metabolic and cardiovascular disorders, today announced that it has completed enrollment of a pivotal Phase 3 clinical trial of Ophena(TM) (ospemifene), the company's estrogen-free oral therapy in development for the treatment of vaginal symptoms associated with menopause.

Ophena(TM) is a new-generation selective estrogen receptor modulator (SERM) for postmenopausal vaginal syndrome (PVS), a common condition in postmenopausal women sometimes referred to as vaginal atrophy and characterized by vaginal symptoms such as dryness, irritation and sexual pain. Phase 2 clinical trials with Ophena(TM) demonstrated beneficial effects on vaginal epithelium and bone markers. In addition, in a Phase 2 trial, Ophena(TM) did not induce hot flashes in postmenopausal women when compared to placebo.

Patient enrollment for the randomized, double-blind study has reached 827 post-menopausal women at 80 trial centers throughout the United States. Women participating in the study are treated with either a 30- or 60-mg once daily oral dose of Ophena(TM) or placebo for 12 weeks. The study is the first of two pivotal Phase 3 efficacy trials planned for the compound.

"Completion of enrollment for this first Ophena(TM) Phase 3 trial is a significant development milestone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx. "In this pivotal study we are seeking to confirm the beneficial vaginal effects already seen in our Phase 2 program. Millions of women suffer from such post-menopausal symptoms for which there are no oral non-estrogen treatments available. Ophena(TM) is specifically designed to address a major unmet
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Celsion Completes Enrollment in Phase I Liver Cancer Study
3. LANI completes Phase I in Japan and to commence Phase I in UK
4. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
5. Monitoring Patient Glucose Levels: New Advances in software make it easier
6. Managing Preanalytical Processes for Patient Safety
7. Hematology Analyzers Simple, Sophisticated Technology Serving All Patients
8. Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... -- China Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ... China based on the number of directly operated ... Meeting of Shareholders (the "AGM") on October 22, 2014 at 10:00 ... room of the Company at 6th Floor, Tower B, Xinnengyuan Building, ... Guangdong Province 518054, People,s Republic of China ...
(Date:9/19/2014)... 2014  Today DePuy Synthes Companies of Johnson ... systems featuring its proprietary variable angle locking technology. ... to match patient anatomy and fracture pattern and ... systems are being introduced in conjunction with the ... the International Federation of Foot & Ankle Societies ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 2DePuy Synthes Proprietary Variable Angle Locking Technology Now Available To Treat Calcaneal Fractures And Medial Column Fusion Procedures 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... The recent ruling by federal judge Royce C. Lamberth halting ... disease research but not necessarily for arthritis.  A key note ... Treatment of Osteoarthritis of the Knee " will be made ... American College of Rheumatology in Atlanta. Osteoarthritis (OA) ...
... CHARLOTTE, N.C., Aug, 24 BlueDot Medical, Inc. ... BlueDot was ranked #2,572 on the annual list ... and #213 among healthcare businesses. (Logo: ... ) "We are extremely proud to ...
Cached Medicine Technology:Embryonic Stem Cell Research in the Toilet, According to Arthritis Treatment Center 2
(Date:9/21/2014)... St. Petersburg, FL (PRWEB) September 22, 2014 ... Beauty® outlines the top 3: , 1) Dry Brushing improves ... 2) Dry Skin Brushing exfoliates dead cells, toxins and debris ... with lymphatic drainage and movement , While Body Brushing can ... facial skin. Because it is more fragile and thinner, ...
(Date:9/21/2014)... birth the birth of an infant prior to ... problem that has increased over the past two decades. ... Prevention (CDC), preterm birth affects nearly 500,000 babies each ... U.S. While medical care has improved survival rates for ... the neurodevelopmental outcomes of preterm infants. , Research led ...
(Date:9/21/2014)... Instituting a partial smoking ban at a homeless shelter ... levels, an indicator of exposure to cigarette smoke, and ... to new research. The University of Texas Health Science ... week in the journal Addictive Behaviors . , ... fallen to 18 percent among adults, but among homeless ...
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... was originally launched in 1997, and is used ... children and adults. Its active ingredient, budesonide, is ... the corticosteroid receptor. AstraZeneca’s Pulmicort franchise includes the ... older than six years of age, Pulmicort Respules ...
(Date:9/21/2014)... authorities focus on the physical activity benefits of active ... reveals that for children, playing has no goal ... is fun, done alone or with friends, and it ... also to combat boredom, sadness, fear, or loneliness." "By ... put aside several aspects of play that are beneficial ...
Breaking Medicine News(10 mins):Health News:Gorgeous Skin: 3 Top Benefits of Dry Face Brushing from Sublime Beauty® 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 2Health News:Research evaluates neurodevelomental and medical outcomes in single family room NICU 3Health News:UTHealth researchers study impact of smoking ban in homeless shelter 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Pulmicort Asthma Market (Epidemiology, Etiology, Symptoms, Diagnosis, Pathology) Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Narrow focus on physical activity could be ruining kids' playtime 2
... help people in coping with their stressful medical experiences ... that when people go through a stressful medical event ... They explained that patients who tend to take solace ... less stressful than those who are spiritually angry or ...
... new class of breast cancer drugs had yesterday won the ... the ‘gold standard’ Tamoxifen.// ,The National Institute for ... on the appraisal for the use of three types of ... was explained that these drugs would act by reducing the ...
... risk of dementia in older women, according to a ... examine //the link between glycosylated hemoglobin and cognitive problems ... issue of the Journal of Nutrition, Health, and Aging. ... diabetes and cognitive problems,” says lead author Kristine Yaffe, ...
... published in the September issue of the American Journal ... genes //responsible for preserving cognition even at the age ... are the first to identify the genetic association with ... defined in many ways, however, we focused on individuals ...
... August, 2006) questions the government over a possible ?300 million ... warns, is already// under pressure on several different fronts. ... least ?1 billion would be created for health research, which ... the NHS Research and Development programme. The combined value of ...
... study to be published in the August 15 issue of ... The Heart Research Institute in Sydney have warned// that a ... of burger can be sufficient enough to cause heart attack. ... 18 and 40, the researchers were shocked to find that ...
Cached Medicine News:Health News:High Blood Sugar Increases Dementia Risk 2Health News:High Blood Sugar Increases Dementia Risk 3Health News:Genes And Aging 2Health News:NHS research under pressure, and could face ?300 million cut, BMA warn 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: